Aura Biosciences, Inc. Fair Value Adjustment of Warrants
Aura Biosciences, Inc. (AURA) reported Fair Value Adjustment of Warrants of -$61.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Cash Flow
us-gaap:FairValueAdjustmentOfWarrants · last filed 2022-08-11
- Aura Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2022-06-30 was -$61.00K, a 2133.33% decline year-over-year.
- Aura Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2022-03-31 was $44.00K.
- Aura Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2021-12-31 was $12.00K.
- Aura Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2021-09-30 was $0.00.
- Aura Biosciences, Inc. fair value adjustment of warrants for fiscal 2021 was $11.00K.
- Aura Biosciences, Inc. fair value adjustment of warrants for fiscal 2020 was -$3.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$61.00K 10-Q · filed 2022-08-11 | -$16.00K 10-Q · filed 2022-08-11 | -$5.00K derived: sum of 3 quarters · filed 2022-08-11 | -$5.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | $44.00K 10-Q · filed 2022-05-12 | $56.00K derived: sum of 2 quarters · filed 2022-05-12 | $56.00K derived: sum of 3 quarters · filed 2022-05-12 | $59.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $12.00K derived: sum of 2 quarters · filed 2022-03-23 | $15.00K derived: sum of 3 quarters · filed 2022-08-11 | $11.00K 10-K · filed 2022-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-24 | $3.00K derived: sum of 2 quarters · filed 2022-08-11 | -$1.00K 10-Q · filed 2021-11-24 | |
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-11 | -$1.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$4.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$3.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |